Oxford Biomedica
Total Voting Rights
Oxford, UK - 01 May 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or
"the Company"), a quality and innovation-led cell
and gene therapy CDMO, today announces
that in accordance with the FCA's
Disclosure Guidance and Transparency Rule 5.6.1R, the Company's
issued share capital as at the close of business on 30 April 2024
consisted of 100,000,296 ordinary
shares of 50 pence each ("Ordinary Shares"). There are no Ordinary
Shares held in treasury.
Accordingly, the total number of
voting rights in Oxford Biomedica at the date of this notice
is 100,000,296.
The above figure
(100,000,296) may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, Oxford Biomedica
under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led cell and gene therapy CDMO with a mission to enable
its clients to deliver life changing therapies to patients around
the world.
One of the original pioneers in cell and gene
therapy, the Company has more than 25 years of experience in viral
vectors; the driving force behind the majority of gene therapies.
The Company collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenoviral vectors, and other viral
vector types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on
LinkedIn
and YouTube.